Menu

Research

The tables below indicate the effectiveness of the SCENAR in a wide range of medical conditions. Individual results may vary.

1. Summary Results of 50,000 Cases in Medical Literature
Percentage Success Rate by Category

Circulatory 82%
Musculoskeletal 79%
Respiratory 84%
Digestive 93%
GU 89%
Ob-Gyn 78%
Nervous 81%
ENT 82%
Eye 93%
Dental 91%
Dermatological 68%
CA Palliative 80%
Misc 81%

2. Summary of SCENAR results
published by Yori Gorfinkle, MD. Taganrog, Russia

Percent cured 84.91%
Percent Improved 94.75%
Average Treatments 12
Average total time (hours) 4.06
Total number of cases 17,309

Details:

Diseases of the Circulation System                
  # Patients Complete Cure Significant Improvement Moderate Improvement Slight Improvement No Result % Cured % Improved
Transient dytonia of blood vessels 682 614 38 10 12 8 90.03 98.83
Essential hypertension 318 261 13 22 8 14 82.08 95.60
Angina pextoris 228 138 42 8 13 14 60.53 88.16
Acute myocadial infarction 31 22 4 3 1 1 70.97 96.77
Sudden cardiac arrest 16 12 0 0 0 4 75.00 75.00
Acute heart failure 48 47 0 0 0 1 97.92 97.92
Ischemic heart disease 92 2 69 4 14 4 2.17 95.65
Cardialgia NOS 104 99 1 1 1 2 95.19 98.08
Hemorrhoids 408 391 14 1 1 1 95.83 99.75
Totals 1245 1586 180 49 50 62 72.46 93.37

 

Diseases of Digestive System                
  # Patients Complete Cure Significant Improvement Moderate Improvement Slight Improvement No Result % Cured % Improved
Gastritis and duodenitis 1,018 1002 12 1 1 2 98.43 99.80
Gastric and Duodenal Ulcers 341 228 13 26 2 12 66.86 78.89
Enteritis (mainly non-infectious) 182 182 0 0 0 0 100 100
Colitis 302 263 20 10 3 6 87.09 98.01
Cholecystitis 218 145 6 10 3 4 66.51 75.23
Hepatitis/Hepatic Failure 48 47 0 0 0 1 97.92 97.92
Pancreatitis (Acute and Chronic) 63 63 0 0 0 0 100 100
Totals 2,172 1,930 51 47 9 25 88.12 92.84

 

Diseases of the Ear                
  # Patients Complete Cure Significant Improvement Moderate Improvement Slight Improvement No Result % Cured % Improved
Otitis 144 144 0 0 0 0 100 100
Hearing Loss 85 68 11 4 0 2 80.00 97.65
Abnormal auditory perception 116 98 4 2 4 8 84,48 93.10
Totals 345 310 15 6 4 10 89.86 97.10

 

Diseases & Trauma of Musculoskeletal System                
  # Patients Complete Cure Significant Improvement Moderate Improvement Slight Improvement No Result % Cured % Improved
Arthropathies (arthritis, arthrosis, etc.) 1,238 753 280 114 61 30 60.82 97.58
Dorsopathies (deformations, spondylosis) 2,352 2,048 252 35 17 2 87.07 100
Radiculopathy (trapped nerve) 1,820 1,670 102 40 6 2 91.76 99.89
Neuralgia (cervicalgia, lumbago, sciatica) 605 582 17 6 0 0 96.20 100
Myositis 840 839 0 0 0 1 99.88 99.88
Ligament strain 108 108 0 0 0 0 100 100
Superficial injury of soft tissues 325 325 0 0 0 0 100 100
Unknown pain (soft tissues and bones) 32 28 1 1 1 1 87.50 96.88
Totals 7,320 6,353 652 196 85 36 90.40 99.28

 

Diseases of Respiratory System                
  # Patients Complete Cure Significant Improvement Moderate Improvement Slight Improvement No Result % Cured % Improved
Acute nasopharyngitis (common cold) 608 601 6 0 0 1 98.85 99.84
Acute upper respiratory viral infection 345 345 0 0 0 0 100 100
Influenza 104 104 0 0 0 0 100 100
Acute Tonsilititis and pharyngitis 328 314 14 0 0 0 95.73 100
Acute Sinusitis 221 218 3 0 0 0 98.64 100
Acute Laryngitis and traceitis 402 380 18 2 0 0 94.53 99.50
Acute Bronchitis 615 562 24 15 7 7 91.38 98.86
Pneumonia 138 116 14 2 3 3 84.06 97.83
Asthma 82 31 15 22 7 7 37.80 91.46
Acute respiratory failure 15 14 0 0 0 1 93.33 93.33
Acute edema of the lung 12 11 0 0 0 1 91.67 91.67
Pleurisy 38 22 2 1 1 1 86.84 97.37
Totals 2,908 2,729 96 42 18 21 89.40 97.49

 

Urogenital Diseases (Female)                
  # Patients Complete Cure Significant Improvement Moderate Improvement Slight Improvement No Result % Cured % Improved
Mastopathy 264 220 8 16 3 18 83.33 93.56
Acute Mastitis 88 88 0 0 0 0 100 100
Salpingitis/ovarian cyst 608 604 1 1 1 1 99.34 99.84
Endometriosis 126 98 4 10 7 7 77.78 94.44
Fibromyoma of uterus 201 116 38 21 3 23 57.71 88.56
Erosion of cervix uteri 120 119 0 0 0 1 99.71 99.71
Dysmernorrea (menstrual cycle disorders) 180 112 30 12 0 26 62.22 85.56
Female infertility 86 63 0 0 0 23 73.26 73.26
Frigidity 38 18 6 7 1 6 47.37 84.21
Totals 1,447 1,438 87 67 15 105 77.11 90.63

 

Urogenital Diseases (Male)                
  # Patients Complete Cure Significant Improvement Moderate Improvement Slight Improvement No Result % Cured % Improved
Pyelonephritis (Acute and Chronic) 402 384 4 7 3 4 95.52 99.00
Urinary calculi 161 140 7 6 5 3 86.96 98.14
Cystitis 208 207 0 0 0 1 99.52 99.52
Urethritis 24 22 1 0 0 1 91.67 95.83
Prostatitis (Acute and Chronic) 605 602 3 0 0 1 99.50 100
Hyperplasia of prostate 88 63 7 3 8 7 71.59 92.05
Male infertility 62 44 0 0 0 18 70.97 70.97
Impotence 322 269 14 0 0 48 80.75 85.09
Totals 1,872 1,722 36 16 16 83 87.06 92.58

 

In Europe and USA the SCENAR is registered as the following device:

Europe:
The SCENAR 97.4+ has been awarded the CE mark and complies with the European Medical Directive (93/42/EEC). This documentation states it is:

A device for monitoring, treating and alleviating non-specific disease, injury or handicap by supplying low-level electrical energy to the body system in a form that may reduce pain, oedema and inflammation in a manner that allows the natural resources of that body to restore homeostasis more rapidly than if it were left alone......(by) electrical action on the skin surface activating tissues in the "somatic and autonomous" nervous system...(leading to) the possibility of a therapeutic effect in addition to mediating pain by the production of endorphins.
In simple terms Scenar Treatment is currently permitted to claim positive efficacy for pain relief and pain management for to use in all countries in the European Union, and is a 'safe device'.

USA:
SCENAR 97.4+ Biofeedback-controlled. Regulated by the US FDA under 21 CFR 882.5050, Generic Name: Device, Biofeedback, Product Code HCC, Class II exempt from 510(K) pre-market notification according to FDA Notice FR21ja98-84 as a battery-powered, professional use device for relaxation training and muscle education.
A Class III FDA approval is pending. Prior to that approval, the manufacturer can only promote use for above in the US.

 Printbare informatie Life Balance

(meer)



 Resultaten
Resultaten van Life Balance clienten.

(meer)




e3